Compounded and FDA-approved GLP-1 medications are not the same thing.
FDA-approved medications have gone through a formal review process evaluating their safety, effectiveness, manufacturing quality, labeling, dosing, and stability for specific indications. Compounded medications are prepared for individual patient needs under specific circumstances, but they are not FDA approved and do not undergo the same premarket review.
That distinction has become especially important with medications containing semaglutide and tirzepatide.
During major GLP-1 shortages, compounded versions became more widely available because federal law can allow certain compounding when an approved medication is in shortage. Those circumstances have changed. The FDA determined that the tirzepatide injection shortage was resolved in December 2024 and the semaglutide injection shortage was resolved in February 2025. The temporary enforcement-discretion periods associated with those shortages subsequently ended.
As of 2026, the FDA continues to emphasize that compounded GLP-1 drugs should generally be reserved for situations in which a patient’s medical needs cannot be met by an available FDA-approved medication.
That does not mean every compounded medication is inherently unsafe or inappropriate. Compounding has a legitimate role in medicine. It does mean patients should understand exactly what they are receiving, why it is being compounded, who is preparing it, and how that option differs from an FDA-approved product.
Here is what you need to know.
What Are GLP-1 Medications?
GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone involved in appetite regulation, digestion, insulin secretion, and blood glucose control.
Medications that activate GLP-1 receptors can help:
- Reduce appetite
- Increase feelings of fullness
- Slow gastric emptying
- Improve glucose regulation
- Support clinically meaningful weight loss in appropriate patients
Semaglutide is a GLP-1 receptor agonist.
Tirzepatide acts on both GLP-1 and glucose-dependent insulinotropic polypeptide, or GIP, receptors, so it is technically a dual GIP/GLP-1 receptor agonist.
These medications were initially associated primarily with diabetes treatment, but specific formulations have since received FDA approval for additional indications.
For example, Wegovy, which contains semaglutide, is approved for chronic weight management in certain patients. In 2024, the FDA also approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in certain adults with cardiovascular disease and overweight or obesity.
Zepbound, which contains tirzepatide, is approved for chronic weight management in qualifying adults. It was also approved in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity.
This brings us to an important point:
The molecule, formulation, indication, dose, delivery system, and regulatory status all matter.
Simply seeing the word “semaglutide” or “tirzepatide” on a label does not mean two products have been evaluated in the same way.
What Is an FDA-Approved GLP-1 Medication?
An FDA-approved drug has been evaluated by the FDA before it is allowed to be marketed for its approved indication.
Manufacturers must provide evidence addressing areas such as:
- Safety
- Effectiveness
- Appropriate dosing
- Manufacturing processes
- Product quality
- Purity
- Stability
- Packaging
- Storage requirements
- Labeling
- Known adverse effects
- Drug interactions
Approval does not mean a medication is completely free of risk.
No effective medication is.
Instead, FDA approval means that the agency has reviewed evidence and determined that the medication’s benefits outweigh its known and potential risks when used according to its approved labeling in the appropriate population.
FDA-approved GLP-1 medications also come with standardized prescribing information describing how the medication should be initiated, titrated, administered, stored, and monitored.
That standardization can be particularly important with powerful medications that require gradual dose escalation.
Examples of FDA-Approved Semaglutide and Tirzepatide Products
Several brand-name medications contain these active ingredients, but their FDA-approved indications are not interchangeable.
Semaglutide
FDA-approved semaglutide products include:
Ozempic
Primarily used in adults with type 2 diabetes, with additional approved cardiovascular and kidney-related indications for specific populations.
Wegovy
Approved for chronic weight management in qualifying patients, along with its cardiovascular risk-reduction indication in certain adults.
Rybelsus
An oral semaglutide product used in type 2 diabetes.
Tirzepatide
FDA-approved tirzepatide products include:
Mounjaro
Approved to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.
Zepbound
Approved for chronic weight management in qualifying adults and for moderate to severe obstructive sleep apnea in adults with obesity.
The fact that two products contain the same underlying drug molecule does not automatically mean they have the same approved indication.
What Is a Compounded GLP-1 Medication?
Compounding is the practice of preparing a medication to meet a specific patient’s clinical needs.
It is not unique to GLP-1 medications.
Compounding pharmacies have long played an important role when commercially manufactured medications cannot meet an individual patient’s needs.
For example, a physician might prescribe a legitimately compounded medication when a patient requires a dosage form or ingredient configuration that is not available commercially.
But compounded drugs differ fundamentally from FDA-approved drugs.
The FDA does not approve compounded medications before they reach patients.
According to the FDA, compounded products do not undergo its premarket review for safety, effectiveness, or quality.
That does not mean compounding occurs without regulation. Depending on how a product is compounded, facilities can be subject to state pharmacy oversight, federal requirements, and sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
But those frameworks are not equivalent to FDA drug approval.
Why Did Compounded Semaglutide and Tirzepatide Become So Common?
The enormous demand for GLP-1 medications created significant supply shortages.
When an FDA-approved drug appears on the FDA’s Drug Shortages List, certain restrictions that normally prevent compounders from producing essentially copies of commercially available drugs may be relaxed under specific circumstances.
This created a much larger market for compounded semaglutide and tirzepatide during the shortage period.
But the shortage status changed.
The FDA determined the tirzepatide injection shortage was resolved on December 19, 2024, following a reevaluation of its earlier decision.
The FDA then determined the semaglutide injection shortage was resolved on February 21, 2025.
Temporary enforcement-discretion periods allowed certain compounders time to transition after these shortages ended, but those periods have since expired.
As of April 2026, the FDA stated that tirzepatide and semaglutide were not on its drug shortage list and were not on the agency’s 503B bulks list.
This matters because shortage-related mass compounding is different from preparing a compounded medication for a documented individual clinical need.
Compounded vs. FDA-Approved GLP-1 Medications: The Major Differences
1. FDA Approval
This is the most important difference.
FDA-approved GLP-1 medication:
Has undergone FDA review before marketing for safety, effectiveness, manufacturing quality, labeling, dosing, and other factors.
Compounded GLP-1 medication:
Has not been individually reviewed or approved by the FDA before being dispensed to patients.
The FDA specifically warns against marketing language implying that a compounded GLP-1 is “FDA approved,” equivalent to an FDA-approved medication, or effectively a generic version of one.
There are currently no FDA-approved generic versions of medications such as Wegovy or Zepbound simply because a compounded preparation contains semaglutide or tirzepatide.
2. Manufacturing and Quality Controls
FDA-approved medications are manufactured according to standardized processes subject to regulatory requirements.
Patients should expect the approved product to meet established specifications for:
- Strength
- Purity
- Stability
- Sterility when applicable
- Packaging
- Storage
- Delivery system
Compounded products can vary based on the pharmacy or outsourcing facility preparing them.
This makes the quality of the compounding source particularly important.
Patients should know which pharmacy actually prepared the medication rather than relying only on the name of the clinic, wellness company, or telehealth platform selling the program.
The FDA has warned about fraudulent products labeled as compounded semaglutide or tirzepatide, including products that named pharmacies that did not actually produce them.
3. Dosing and Delivery
Approved injectable GLP-1 products typically use standardized dosing systems.
Some compounded medications are instead supplied in multidose vials with syringes.
That can introduce another opportunity for error because patients may need to convert among:
- Milligrams
- Milliliters
- Medication concentration
- Syringe “units”
The FDA has received reports of compounded semaglutide dosing errors in which patients administered substantially more medication than prescribed.
In reported cases, some patients accidentally administered five to 20 times the intended dose. Other errors involved clinicians incorrectly converting milligrams into syringe units or milliliters. Some cases required medical care or hospitalization.
Symptoms reported after dosing errors have included nausea, vomiting, abdominal pain, dehydration, fainting, pancreatitis, and gallstones.
This does not mean every vial-based compounded medication will result in a dosing mistake.
It means clear instructions and patient education are essential.
Are Compounded GLP-1 Medications the Same as Ozempic, Wegovy, Mounjaro, or Zepbound?
No.
This is one of the most important misconceptions to correct.
A compounded preparation containing semaglutide should not simply be described as “generic Ozempic” or “generic Wegovy.”
Likewise, compounded tirzepatide should not automatically be described as generic Mounjaro or Zepbound.
FDA-approved products have specific:
- Formulations
- Manufacturing standards
- Delivery systems
- Dosages
- Stability data
- Clinical evidence
- Approved indications
- Prescribing information
The FDA has taken enforcement action against businesses making claims that compounded semaglutide or tirzepatide products were the same as FDA-approved medications or contained the “same active ingredient” in a way that misleadingly suggested FDA review or approval.
Patients deserve accurate language when comparing these options.
What About Semaglutide Sodium and Semaglutide Acetate?
This is another area where patients should pay close attention.
FDA-approved semaglutide medications use the base form of semaglutide.
The FDA has warned that some compounded products have reportedly used semaglutide salt forms, including:
- Semaglutide sodium
- Semaglutide acetate
These are different active ingredients from the semaglutide used in FDA-approved medications.
The FDA states that it does not have information establishing that these salt forms have the same chemical and pharmacologic properties as the active ingredient used in approved medications, and the agency has said it is not aware of a lawful basis for using those salt forms in compounding.
If you are prescribed compounded semaglutide, asking what form of semaglutide is being used is reasonable.
Are Compounded GLP-1 Medications Dangerous?
The answer requires more nuance than either “yes” or “no.”
Compounded medications serve legitimate medical purposes.
The problem occurs when compounded medications are treated as though they are interchangeable with FDA-approved medications without acknowledging differences in regulatory review and quality assurance.
Potential concerns with compounded GLP-1 products can include:
- Incorrect dosing
- Variable concentrations
- Confusing instructions
- Contamination or sterility concerns
- Improper storage or shipping
- Use of inappropriate active ingredients
- Misleading labeling
- Fraudulent products
- Lack of adequate clinical oversight
The FDA has also received complaints about injectable compounded GLP-1 medications arriving warm or inadequately refrigerated. Because storage conditions can affect drug quality, the agency recommends patients not use injectable GLP-1 products that arrive warm when appropriate refrigeration was required.
As of May 31, 2026, the FDA reported receiving 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide.
Those numbers should be interpreted carefully.
An adverse-event report does not establish that the medication caused the event, and reporting systems cannot directly tell us the incidence rate without knowing the total number of exposed patients. The FDA also notes that adverse events associated with compounded products may be underreported because many state-licensed pharmacies are not federally required to submit adverse-event reports.
FDA-Approved GLP-1 Medications Also Have Risks
Choosing an FDA-approved medication does not eliminate side effects.
GLP-1-based medications can produce significant adverse effects even when manufactured and administered correctly.
Common gastrointestinal effects can include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal discomfort
- Indigestion
Depending on the specific medication, labeling can also include warnings or precautions involving conditions such as pancreatitis, gallbladder disease, kidney injury related to volume depletion, hypoglycemia when used with certain diabetes medications, and other complications.
Wegovy and Zepbound labeling also contain boxed warnings related to thyroid C-cell tumors observed in rodents, and these medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
A prescription should therefore come with medical screening, dose management, and follow-up rather than simply access to an injection.
What Does “FDA-Registered Compounding Pharmacy” Mean?
Be careful with this phrase.
Marketing terminology surrounding compounding can be confusing.
A business may describe medications as coming from an “FDA-registered” or even “FDA-licensed” facility.
That does not mean the compounded medication itself is FDA approved.
In a 2026 warning letter, the FDA specifically noted that the Federal Food, Drug, and Cosmetic Act does not create an “FDA-approved” or “FDA-licensed” designation for compounding pharmacies or outsourcing facilities.
Some outsourcing facilities register with the FDA under section 503B, but registration does not transform individual compounded products into FDA-approved drugs.
Patients should distinguish between:
Facility status and drug approval status.
They are not the same thing.
When Might Compounding Still Be Appropriate?
Compounding remains part of legitimate medical practice.
The FDA states that a compounded drug may be appropriate when a patient’s medical needs cannot be met by an FDA-approved medication.
That determination should be individualized.
Under section 503A, for example, compounding generally involves preparation for an identified individual patient based on a prescription, and federal restrictions apply to regularly making essentially copies of commercially available medications.
This is different from manufacturing large quantities of a compounded drug and broadly promoting it as a cheaper equivalent of an FDA-approved product.
A qualified clinician should be able to explain why the compounded option is medically appropriate for you.
Questions to Ask Before Taking a Compounded GLP-1 Medication
If compounded medication is being considered, ask specific questions rather than assuming all GLP-1 programs operate the same way.
Consider asking your clinician:
1. Why am I being prescribed a compounded medication instead of an FDA-approved option?
There should be a clinical reason rather than only marketing language.
2. Which pharmacy compounds the medication?
Get the actual pharmacy name.
3. Is that pharmacy appropriately licensed?
Patients can verify licensing through the relevant state board of pharmacy.
4. What active ingredient is being used?
For semaglutide, specifically ask whether it is semaglutide base rather than a salt such as semaglutide sodium or acetate.
5. What is the medication concentration?
Do not rely only on syringe units.
Understand how the prescribed milligram dose corresponds to the amount you inject.
6. Can you demonstrate exactly how much I should inject?
Especially when using multidose vials.
7. What is the titration schedule?
GLP-1 medications are generally increased gradually to improve tolerability.
8. How should the medication be stored?
Ask what to do if the shipment arrives warm, damaged, or late.
9. What side effects should trigger a call to the medical team?
Your provider should have a clear process for handling symptoms or questions.
10. Who monitors my progress?
Good GLP-1 care should involve more than shipping medication.
The Bigger Issue: GLP-1 Treatment Is More Than the Prescription
Whether someone uses an FDA-approved or appropriately compounded medication, the prescription is only one part of treatment.
The goal should not simply be to make the scale move downward as quickly as possible.
A comprehensive weight-management strategy should consider:
- Protein intake
- Resistance training
- Muscle preservation
- Sleep
- Blood glucose
- Blood pressure
- Lipids
- Gastrointestinal tolerance
- Hydration
- Micronutrient intake
- Medication interactions
- Eating behavior
- Long-term weight maintenance
Rapid weight loss without adequate nutrition and resistance training can result in loss of lean mass along with body fat.
For adults in their 40s, 50s, and beyond, preserving muscle becomes particularly important for metabolic health, physical function, and long-term independence.
That is why simply comparing the monthly price of two injections can miss the larger question.
What kind of clinical care surrounds the medication?
Compounded vs. FDA-Approved GLP-1s: Which Is Better?
For most patients who can appropriately use and access an FDA-approved medication, the FDA recommends using the approved product when available and medically appropriate.
That provides:
- FDA-reviewed manufacturing and quality
- Standardized dosing
- Established labeling
- Evidence from controlled clinical trials
- Defined approved indications
- More standardized delivery systems
Compounding may still have a legitimate role when a patient’s individual medical needs cannot be met by an available FDA-approved product.
What patients should avoid is assuming that a compounded medication advertised online is automatically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
It is not.
Red Flags When Shopping for GLP-1 Treatment Online
The rapid growth of online GLP-1 programs has created legitimate options as well as questionable ones.
The FDA recommends caution if a company:
- Claims its compounded medication is the same as an FDA-approved medication
- Offers unusually deep discounts
- Does not require medical screening
- Does not require a prescription
- Does not provide access to a licensed clinician for questions
- Sends products with suspicious labels or pharmacy information
- Provides medications without clear instructions
- Ships medication in damaged packaging or inappropriate conditions
Another major red flag is anything sold as “research use only” or “not for human consumption” while simultaneously being marketed to consumers for weight loss.
The FDA warns consumers not to purchase these products because their quality is unknown and they may be harmful.
The Bottom Line
Compounded and FDA-approved GLP-1 medications should not be treated as interchangeable.
FDA-approved medications such as Wegovy, Ozempic, Mounjaro, and Zepbound undergo a formal regulatory review process evaluating safety, effectiveness, quality, manufacturing, dosing, and labeling for their respective indications.
Compounded medications do not undergo that same FDA approval process.
Compounding still has an important medical role, particularly when an individual patient’s clinical needs cannot be met with an available FDA-approved medication. But widespread compounded semaglutide and tirzepatide availability expanded largely during shortages that have since been declared resolved.
For patients considering GLP-1 therapy, the better question is not simply:
“Where can I get semaglutide or tirzepatide?”
It is:
“Which treatment is appropriate for my health history, who is prescribing it, where is it coming from, how will my dose be managed, and what kind of follow-up care will I receive?”
Those questions matter whether your goal is weight loss, better metabolic health, diabetes management, cardiovascular risk reduction, or long-term health optimization.
GLP-1 medications can be powerful clinical tools.
They should also be treated like powerful medications.
Frequently Asked Questions
Is compounded semaglutide FDA approved?
No. Compounded semaglutide products are not FDA approved. The FDA does not review individual compounded drugs for safety, effectiveness, and quality before they are marketed.
Is compounded tirzepatide the same as Zepbound?
No. A compounded tirzepatide product should not be considered identical or equivalent to FDA-approved Zepbound. Zepbound has undergone FDA review for specific indications, formulations, dosing, manufacturing, quality, and labeling.
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Ozempic and Wegovy are FDA-approved medications containing semaglutide. A compounded semaglutide preparation is not an FDA-approved generic version of either medication.
Why was compounded semaglutide so widely available?
Demand for semaglutide exceeded supply for several years. Federal rules can permit certain compounding during an FDA-recognized drug shortage. The FDA declared the semaglutide injection shortage resolved on February 21, 2025.
Is tirzepatide still in shortage?
The FDA determined the tirzepatide injection shortage was resolved in December 2024. The shortage-related enforcement-discretion periods for compounders subsequently ended.
Can compounded GLP-1 medications still be prescribed?
They may still be appropriate in certain individualized circumstances when a patient’s medical needs cannot be met by an available FDA-approved drug and applicable compounding laws are satisfied. The legality and appropriateness depend on the specific circumstances.
Are FDA-approved GLP-1 medications risk-free?
No. FDA approval does not mean risk-free. GLP-1 and GIP/GLP-1 medications can cause side effects and may be inappropriate for certain patients. Medical screening, appropriate titration, and ongoing monitoring remain important.
What should I check before using compounded semaglutide?
Ask why compounding is clinically necessary, identify the actual compounding pharmacy, verify licensure, confirm the active ingredient and concentration, understand the dose in milligrams and volume, review storage requirements, and make sure you have access to a licensed clinician for follow-up.
Medical Disclaimer
This article is for educational and informational purposes only and should not be considered medical advice, diagnosis, or a recommendation for any specific medication. GLP-1 medications are prescription drugs and may not be appropriate for everyone. Treatment decisions should be made with a qualified healthcare professional who can review your medical history, medications, laboratory data, treatment goals, contraindications, and individual risk factors.
References
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Updated 2026.
- U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize.
- U.S. Food and Drug Administration. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products.
- U.S. Food and Drug Administration. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. February 6, 2026.
- U.S. Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight.
- U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea.
- U.S. Food and Drug Administration. Compounding When Drugs Are on FDA’s Drug Shortages List.
